Evidence map›Paper›PMID 38261336›Full record

ArticleJournal of comparative effectiveness research2024

Visualizing the target estimand in comparative effectiveness studies with multiple treatments.

Gabrielle Simoneau, Marian Mitroiu, Thomas Pa Debray, Wei Wei, Stan Rw Wijn, Joana Caldas Magalhães, Justin Bohn, Changyu Shen, Fabio Pellegrini, Carl de Moor

Open access · diamondAbstract read
In one paragraph

Article in Journal of comparative effectiveness research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Gabrielle SimoneauBiogen Canada, Toronto, ON, Canada.ORCID 0000-0001-9310-6274
Marian MitroiuBiogen International GmbH, Baar, Zug, 6340, Switzerland.ORCID 0000-0002-6479-4757
Thomas Pa DebrayJulius Centre for Health Sciences & Primary Care, University Medical Centre, University of Utrecht, Utrecht, 3584CG, The Netherlands.ORCID 0000-0002-1790-2719
Wei WeiBiogen International GmbH, Baar, Zug, 6340, Switzerland.
Stan Rw WijnSmart Data Analysis & Statistics, Utrecht, 3524HM, The Netherlands.ORCID 0000-0003-3782-6677
Joana Caldas MagalhãesSmart Data Analysis & Statistics, Utrecht, 3524HM, The Netherlands.
Justin BohnJohnson & Johnson, New Brunswick, NJ, USA.
Changyu ShenBiogen, Cambridge, MA 02142, USA.ORCID 0000-0002-4444-0943
Fabio PellegriniBiogen Spain, Madrid, Spain.ORCID 0000-0001-5705-8615
Carl de MoorBiogen, Cambridge, MA 02142, USA.ORCID 0000-0002-6188-0254
Centraal Bureau voor de Statistiek · NLBiogen (Switzerland) · CHBiogen (United States) · USJohnson & Johnson (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

CrotonatesHydroxybutyratesMultiple SclerosisMultiple Sclerosis, Relapsing-RemittingNitrilesToluidinesDimethyl FumarateFingolimod HydrochlorideHumansImmunosuppressive AgentsCrotonatesDimethyl FumarateFingolimod HydrochlorideHydroxybutyratesImmunosuppressive AgentsNitrilesteriflunomideToluidinescomparative effectivenessmatchingmultiple sclerosispropensity scorevisualization

Identifiers

PMID38261336
PMCPMC10842272
OpenAlexW4391134143

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.